Shire has a 60-year-long heritage of leadership in healthcare.1

Shire is a global leader in the development and manufacturing of therapies for haematology. Shire has a decades-long heritage of bringing innovative therapeutics to the haemophilia community. We develop a deep understanding of each patient's journey in order to deliver transformative and personalised therapies to improve the lives of patients with haemophilia and other bleeding conditions.

Because patients are at the center of everything we do, we work with public and private partners in communities around the world to expand access to treatments and elevate the standards of care.

At Shire, we believe in a world with endless possibilities for patients, where they can dream big and live life to the fullest.

A JOURNEY OF ACHIEVEMENTS

First system for separating plasma from whole blood and storing1

1941

First system for separating plasma from whole blood and storing1

1941
1968

Commercially produced factor VIII concentrate1

Therapy for people with haemophilia and antibodies2

1977

Inclusion of heat
treatment in the manufacture of
factor VIII1

1983

Purification of factor VIII by chemical and monoclonal techniques1

1988

Production of factor VIII
by recombinant
technology1

1992

Recombinant production of factor VIII without addition of human or animal proteins1

2003

SHIRE'S QUEST FOR TOMORROW

PIPELINE

Polysialylation recombinant FVIII6

BAX 826

Factor VIII Gene-Therapy-
Based Treatment8

BAX 888
Timeline of Shire's product pipeline is for illustrative purposes only; exact approval dates are unknown and subject to regulatory decisions.

References:
1. Baxter International Inc. Baxter history. http://www.baxter.com/about_baxter/company_profile/history.html. Accessed May 14, 2015. 2. Baxter International Inc. Baxter BioScience fact sheet. http://www.baxter.com/press_room/factsheets/bioscience_factsheet.html. Accessed May 14, 2015. 3. Baxter Healthcare Corporation. Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures [NCT01913405]. US National Institutes of Health Web site. https:// clinicaltrials.gov/ct2/show/NCT01913405. Accessed May 22, 2015. 4. Baxter Healthcare Corporation. Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) [NCT01410227]. US National Institutes of Health Web site. https://clinicaltrials.gov/ct2/show/NCT01410227?term=Pharmacokinetics%2C+Safety+and+Efficacy+of+
Recombinant+Von+Willebrand+Factor+%28rVWF%29+in+the+Treatment+of+Bleeding+Episodes+in+Von+Willebrand+Disease+%28VWD%29&rank=1. Accessed May 22, 2015. 5. Baxter Healthcare Corporation. Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B. US National Institutes of Health Web site [NCT01687608]. https://clinicaltrials.gov/ct2/ show/NCT01687608. Accessed May 22, 2015. 6. Baxter announces restructured agreement with Xenetic Biosciences, further bolstering its broad bleeding disorder pipeline [press release]. Deerfield, IL: Baxter International Inc., January 30, 2014. 7. Baxter BioScience announces positive phase III results for BAX 817, investigational recombinant treatment for hemophilia A and B patients with inhibitors [press release]. Deerfield, IL: Baxter International Inc.; March 13, 2015. 8. Data on file. Baxalta Incorporated.

You are about to enter BaxaltaHematology.com for patients and caregivers
Visit patient site
Return to HCP site
FOR PATIENTS
OR CAREGIVERS
Visit site

Welcome to
Haematology at Shire

This is an international Web site intended for users outside of the U.S.

FOR HEALTHCARE
PROFESSIONALS

You must be a certified healthcare professional
to view this site.
Click below to confirm that you
are a certified healthcare professional.

Visit site
I do not want to leave
BaxaltaHematology.com
FOR PATIENTS
OR CAREGIVERS
Visit site